Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiencies
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Aug 2016
At a glance
- Drugs TBX 1400 (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions
- 04 Aug 2016 Status changed from planning to not yet recruiting.
- 17 Jun 2016 New trial record
- 13 Jun 2016 According to a Taiga Biotechnologies media release, the U.S.FDA granted Orphan Drug Designation to TBX-1400 for the treatment of Severe Combined ImmunoDeficiency in children.